Longterm Survial after Re-challenge with Radiumdichlorid - a Case Report.

Abstract

The life-prolonging effects of Radium223-dichlorid (RaCl2) have been shown in the ALSYMCA trial in 2013 [1] in patients with advanced prostate cancer and dominating bone metastases. Consequently, it was approved by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). Typical initial treatment consists of 6 cycles RaCl2 given in intervals of 4 weeks. As often relapse of the disease can be observed in the treated patients after some time, soon the repeated application of RaCl2 was discussed and analyzed in prospective trials [2]. While toxicity of repeated application of RaCl2 was found to be acceptable and no major issue in most cases, the outcome was shown to be very variable. Therefore, we want to report on one patient in whom bone metastases of an advanced, castration-resistant prostate carcinoma could be stabilized for nearly two years with repeated treatment with RaCl2.